Ki67 targeted strategies for cancer therapy

被引：226
作者：
Yang, C. [1 ]
Zhang, J. [1 ]
Ding, M. [1 ,2 ]
Xu, K. [1 ,2 ]
Li, L. [1 ]
Mao, L. [1 ,2 ]
Zheng, J. [1 ]
机构：
[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China
[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期
关键词：
Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;
D O I：
10.1007/s12094-017-1774-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.
引用
收藏
页码：570 / 575
页数：6
相关论文
共 50 条
  • [1] Ki67 targeted strategies for cancer therapy
    C. Yang
    J. Zhang
    M. Ding
    K. Xu
    L. Li
    L. Mao
    J. Zheng
    Clinical and Translational Oncology, 2018, 20 : 570 - 575
  • [2] The Ki67 dilemma: investigating prognostic cut-offs and reproducibility for automated Ki67 scoring in breast cancer
    Rewcastle, Emma
    Skaland, Ivar
    Gudlaugsson, Einar
    Fykse, Silja Kavlie
    Baak, Jan P. A.
    Janssen, Emiel A. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (01) : 1 - 12
  • [3] Correlation between Ki67 and Breast Cancer Prognosis
    Kontzoglou, Konstantinos
    Palla, Victoria
    Karaolanis, George
    Karaiskos, Ioannis
    Alexiou, Ioannis
    Pateras, Ioannis
    Konstantoudakis, Konstantinos
    Stamatakos, Michael
    ONCOLOGY, 2013, 84 (04) : 219 - 225
  • [4] A novel model for Ki67 assessment in breast cancer
    Quinci Romero
    Pär-Ola Bendahl
    Mårten Fernö
    Dorthe Grabau
    Signe Borgquist
    Diagnostic Pathology, 9
  • [5] A novel model for Ki67 assessment in breast cancer
    Romero, Quinci
    Bendahl, Par-Ola
    Ferno, Marten
    Grabau, Dorthe
    Borgquist, Signe
    DIAGNOSTIC PATHOLOGY, 2014, 9
  • [6] Interlaboratory variability of Ki67 staining in breast cancer
    Focke, Cornelia M.
    Buerger, Horst
    van Diest, Paul J.
    Finsterbusch, Kai
    Glaeser, Doreen
    Korsching, Eberhard
    Decker, Thomas
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 219 - 227
  • [7] A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study
    Bahaddin, Mowafak Masoud
    ANNALS OF MEDICINE AND SURGERY, 2020, 60 : 232 - 235
  • [8] Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer
    Stalhammar, Gustav
    Robertson, Stephanie
    Wedlund, Lena
    Lippert, Michael
    Rantalainen, Mattias
    Bergh, Jonas
    Hartman, Johan
    HISTOPATHOLOGY, 2018, 72 (06) : 974 - 989
  • [9] Strategies for developing Ki67 as a useful biomarker in breast cancer
    Denkert, Carsten
    Budczies, Jan
    von Minckwitz, Gunter
    Wienert, Stephan
    Loibl, Sibylle
    Klauschen, Frederick
    BREAST, 2015, 24 : S67 - S72
  • [10] The potential of ki67 and p53 assessment in development of individualized targeted therapy in breast cancer patients
    Ormenisan, C.
    Kubik, M.
    Legrand, S.
    Kraemer, D.
    Smotherman, C.
    Masood, S.
    PATHOLOGICA, 2015, 107 (3-4) : 177 - 180
12345